MAIA MAIA Biotechnology Inc
Price (delayed)
$1.6
Market cap
$47.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.05
Enterprise value
$37.74M
We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In
Highlights
MAIA's equity has surged by 125% since the previous quarter
MAIA Biotechnology's quick ratio has soared by 73% YoY and by 4.1% from the previous quarter
MAIA Biotechnology's net income has decreased by 18% YoY but it has increased by 10% from the previous quarter
Key stats
What are the main financial stats of MAIA
Market
Valuations
Earnings
Shares outstanding
29.59M
Market cap
$47.34M
Enterprise value
$37.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
11.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.96M
Net income
-$23.25M
EBIT
-$23.25M
EBITDA
-$23.25M
Free cash flow
-$15.7M
Per share
Balance sheet
Liquidity
EPS
-$1.05
EPS diluted
-$1.05
Free cash flow per share
-$0.71
Book value per share
$0.14
Revenue per share
$0
TBVPS
$0.46
Total assets
$10.16M
Total liabilities
$6.52M
Debt
$0
Equity
$3.63M
Working capital
$6.32M
Debt to equity
0
Current ratio
2.65
Quick ratio
2.51
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-231.8%
Return on equity
-3,509.9%
Return on invested capital
N/A
Return on capital employed
-367.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MAIA stock price
How has the MAIA Biotechnology stock price performed over time
Intraday
6.67%
1 week
-3.03%
1 month
-14.89%
1 year
-31.91%
YTD
-19.19%
QTD
4.58%
Financial performance
How have MAIA Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.96M
Net income
-$23.25M
Gross margin
N/A
Net margin
N/A
MAIA Biotechnology's net income has decreased by 18% YoY but it has increased by 10% from the previous quarter
MAIA Biotechnology's operating income has increased by 16% YoY and by 7% from the previous quarter
Growth
What is MAIA Biotechnology's growth rate over time
Valuation
What is MAIA Biotechnology stock price valuation
P/E
N/A
P/B
11.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 30% year-on-year and by 24% since the previous quarter
MAIA's equity has surged by 125% since the previous quarter
Efficiency
How efficient is MAIA Biotechnology business performance
The return on assets is up by 16% since the previous quarter
Dividends
What is MAIA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MAIA.
Financial health
How did MAIA Biotechnology financials performed over time
MAIA's total assets is 56% greater than its total liabilities
The company's current ratio has surged by 73% YoY and by 3.5% QoQ
MAIA Biotechnology's quick ratio has soared by 73% YoY and by 4.1% from the previous quarter
The debt is 100% less than the equity
MAIA's equity has surged by 125% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.